Walleye Capital
STSA

Walleye Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Walleye Capital’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-93,672
Closed -$562K – 3810
2022
Q3 		$562K Sell
93,672
-57,756
-38% -$328K 0.01% 1382
2022
Q2 		$627K Sell
151,428
-110,385
-42% -$389K 0.02% 909
2022
Q1 		$995K Buy
+261,813
New +$1.18M 0.03% 639

Other funds holding STSA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Walleye Capital's STSA Position: Q4 2022 in Review

Walleye Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 93,672 shares — an estimated $562K sold.

Walleye Capital first reported a position in STSA in Q1 2022 and held it in 3 quarters. The position peaked at $995K in Q1 2022. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

  • Walleye Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Walleye Capital sold 93,672 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $562K.
  • Walleye Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Walleye Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $995K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.